Flumivir

Quick links to important sections

Flumivir

Method of action: Antivirals For Systemic Use

Treatment option: Influenza

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flumivir

Quick Facts

Property Description
Active ingredient Oseltamivir (as Oseltamivir phosphate)
Form Capsule (various doses), Powder for Oral Suspension
Pharmacological class Neuraminidase Inhibitor (Antiviral)
General purpose Limiting the spread of influenza (flu) virus
Origin Synthetic (chemically-manufactured)

What Type of Drug is Flumivir?

Flumivir is a trade name for the widely recognized antiviral medication, oseltamivir (INN). It belongs to the specific pharmacological class of drugs known as neuraminidase inhibitors, a group designed to interfere with essential functions of the influenza virus.

This medication is a synthetic compound, manufactured chemically, and has been clinically recognized for its targeted action against the virus's reproductive process. Prompt treatment with this medication can significantly hasten a patient’s return to normal activity levels compared to supportive care alone.

What is Flumivir Made of and Its Available Forms?

The active compound in Flumivir is oseltamivir phosphate. This substance acts as a pro-drug, meaning it is inactive until the body converts it into its potent, therapeutic form (oseltamivir carboxylate) after administration. It is a single-ingredient product.

Designed for oral administration, Flumivir is available as a capsule and a powder for oral suspension (liquid). This versatile dosing allows the medication to be used effectively across a broad patient group, including pediatric patients who may require liquid formulations based on their body weight.

What is the General Purpose of Flumivir?

The general purpose of Flumivir is to control the advance of the influenza virus within the body. Its action focuses on blocking a key enzyme that the virus needs to successfully spread from one cell to another.

By suppressing the virus's ability to multiply and spread, the medication helps to control the overall infection rate. This mechanism is intended to support the body’s natural immune system, contributing to a less severe and potentially shorter course of the flu illness.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Flumivir?

Possible Side Effects and Safety Information

The safety profile of Flumivir (oseltamivir) is described in official regulatory documents by classifying adverse reactions based on their frequency and the body system affected. These classifications establish a systematic understanding of the medicine's potential risk profile.

Adverse Reaction Classifications

Classification Examples of Reactions
Very Common Vomiting, Nausea, Headache, and Pain (in prevention)
Common Diarrhoea, Abdominal pain, Insomnia, Dizziness, Cough, and Rhinorrhoea
Uncommon Hypersensitivity reactions, Dermatitis, and Tympanic membrane disorders

Commonly reported effects primarily involve the Gastrointestinal disorders and Nervous system disorders. Less frequently, reactions may involve the Skin and subcutaneous tissue disorders and the Ear and labyrinth disorders, as listed in the prescribing information.

Clinically Significant Safety Considerations

Regulatory agencies highlight the documentation of serious adverse reactions, although these are rare. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, as well as fulminant hepatitis and hepatic failure. Furthermore, post-marketing reports have documented neuropsychiatric events (e.g., delirium, hallucinations, abnormal behavior), which may occur early during the course of the underlying influenza illness.

Specific population-based safety notes exist, such as the need for dose adjustment in patients with renal impairment due to altered drug exposure. Official labeling also provides constraints, noting that the medication is contraindicated in cases of known hypersensitivity to oseltamivir phosphate and includes restrictions regarding co-administration with the Live Attenuated Influenza Vaccine (LAIV).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Flumivir (oseltamivir) overdose outlines specific documented manifestations and mandated emergency actions, emphasizing the need for immediate medical care in severe cases.

Documented Overdose Manifestations

System Affected Manifestations Listed in Regulatory Labeling
Gastrointestinal System Nausea and vomiting are the most commonly reported signs of overexposure.
Central Nervous System Documented manifestations include seizures, confusion, hallucinations, and severe abnormal behavior.
Severe Systemic Potential for serious skin/hypersensitivity reactions, such as Stevens-Johnson Syndrome, which requires immediate discontinuation of the product.

Required Emergency Actions

Situation Mandated Regulatory Action
Suspected Overdose Contact a poison control center or emergency room at once for guidance.
Life-Threatening Symptoms Immediately call emergency services (911) if the person has collapsed, is having a seizure, has trouble breathing, or cannot be awakened.

Management of overexposure is strictly based on providing symptomatic and supportive treatment. Official regulatory documents indicate that no specific antidote is known for oseltamivir. While common presentations involve the gastrointestinal system, the critical documented risks are the less frequent but severe neuropsychiatric events, including seizures and delirium, which have been reported primarily in pediatric patients. Therefore, close monitoring for signs of abnormal behavior is required for all patients receiving the medication.

Therapeutic Uses of Flumivir

What Flumivir Treats: Main Uses and Benefits

Flumivir (oseltamivir) is commonly used to provide therapeutic support across conditions characterized by periods of heightened symptoms caused by Influenza A and Influenza B viruses. Its primary function is to offer symptomatic relief and is applied in addressing symptomatic discomfort related to the flu infection. This class of drug may assist in lessening symptoms and supporting a reduction in the symptom duration of the illness.

The main indications are the treatment of acute, uncomplicated influenza and the prevention of symptomatic illness after confirmed exposure to the virus.


Quick Facts: Therapeutic Focus

Property Description
Primary Use Used in situations involving certain distressing symptoms of acute Influenza A and B.
Symptom Category Addresses symptom clusters related to systemic imbalance, neurological activity, and physical discomfort.
Context of Use Applied in clinical settings that involve acute or unstable symptom patterns, including post-exposure management.

Managing Acute Flu Illness and Symptom Severity

This therapeutic domain focuses on treatment once flu symptoms have started. The medication helps address the sudden and disruptive cluster of symptoms related to systemic imbalance, including high fever, severe muscle pain (myalgia), profound tiredness, cough, and nasal congestion. Applied in acute clinical settings, the medication's primary therapeutic role is to assist with maintaining functional stability, offering symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.

“Timely supportive care contributes to improved day-to-day comfort during symptomatic periods.”

Preventing Illness After Confirmed Exposure

Flumivir is also relevant in situations requiring post-exposure prophylaxis, where it is used to help manage the development of symptomatic influenza after a person has had close contact with an infected individual. This is a critical use during seasonal outbreaks, particularly for vulnerable populations like children and older adults. This temporary, supportive assistance contributes to easing the overall symptom burden and is relevant for easing the functional strain associated with severe flu manifestations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Flumivir?

Eligibility for Flumivir (oseltamivir) is determined by regulatory agencies based on the patient's age, indication (treatment or prevention), and specific health conditions. This information is derived from official regulatory labeling.


Populations Explicitly Permitted (Age)

Indication Minimum Approved Age (General)
Treatment of Influenza Patients 2 weeks of age and older (some regions approve for full-term neonates)
Prevention (Prophylaxis) Patients 1 year of age and older

Older adults generally face no unique restrictions unless they have severe kidney impairment.


Absolute Restriction (Contraindication)

Flumivir is contraindicated for any patient with a known serious hypersensitivity or allergy to oseltamivir or any other component in the formulation.


Conditions Defining Conditional Use

Use is restricted or conditional in specific populations:

  • Severe Renal Impairment: Requires formal dose modification for adults and adolescents. Use is not recommended for patients with end-stage renal disease not undergoing dialysis.
  • Severe Hepatic Impairment: Use is not recommended.
  • Pregnancy and Lactation: Use is a conditional eligibility status, permitted only if the potential benefit justifies the potential risk, as safety is not fully established.
  • Special Groups: Safety and efficacy are not established in premature infants or for prophylaxis in infants under one year of age.

What should I know about interactions with other medicines?

Flumivir Interactions with other medicines and products

Flumivir (oseltamivir) is generally considered to have a low potential for clinically important drug interactions. Its active form is mainly eliminated by the kidneys through a process called active anionic tubular secretion.

Documented Interactions

Interacting Product Category Specific Agent/Example Interaction Summary
Live Attenuated Influenza Vaccine (LAIV) Intranasal Flu Vaccine (e.g., Fluenz Tetra®) Antiviral activity of Flumivir may reduce the effectiveness of the live vaccine. LAIV should not be administered until at least 48 hours after stopping Flumivir, and Flumivir should generally not be used within two weeks after receiving LAIV.
Anionic Tubular Secretion Inhibitors Probenecid (used for gout) Co-administration results in an approximate two-fold increase in the level of Flumivir's active metabolite in the body. Although this is a significant increase, a dose adjustment is typically not required for patients with normal kidney function.

Products with No Clinically Significant Interaction

Flumivir's active metabolite is not metabolized by the CYP450 enzyme system, which is responsible for breaking down many common medicines. Therefore, co-administration with many routine medicines, including paracetamol (acetaminophen), acetylsalicylic acid (aspirin), and most antacids, is generally not expected to result in clinically significant interactions.

Mechanism of Action

Targeting the Viral Enzyme Neuraminidase

Flumivir's action is defined by its ability to act as a highly specific inhibitor of the viral enzyme neuraminidase, which is essential for the completion of the viral life cycle. This mechanism engages systems where targeted enzymatic adjustment is required to interrupt the pathogen's ability to propagate itself, directly resulting in the restriction of viral release.

Blocking the Cascade of Viral Spread

The inhibition of neuraminidase modifies early molecular steps that shape systemic physiological outcomes by preventing newly formed viral particles from detaching from the surface of the infected host cell. This action is applied to alter pathway activity that may escalate under certain conditions, resulting in a more regulated state within targeted pathways of infection progression.

Modulating the Overall Viral Burden

By halting the continued spread of the virus from cell to cell, the mechanism initiates a suppression of the signaling sequences that lead to high downstream viral replication. This ultimately contributes to a reduction in the total amount of replicating virus in vivo. This core physiological change results in enhanced conditions for viral clearance by the body's natural defenses, which shapes the drug's overall effect profile.

Dosage and Administration Information

How to Use Flumivir (Oseltamivir): Official Administration Guidelines

This information details the official instructions for using Flumivir (oseltamivir), focusing solely on dosing and administration procedures.

Route and Forms Flumivir is administered orally (by mouth). It is available as capsules (30 mg, 45 mg, 75 mg) and as a powder for oral suspension.

Standard Dosing Schedule The schedule depends on the treatment goal and the patient's age and weight:

Goal Standard Adult Dose Frequency and Duration
Treatment 75 mg Twice daily (q12h) for 5 days
Prophylaxis 75 mg Once daily (q24h) for ge 10 days

For treatment, the first dose must be taken within 48 hours of the onset of symptoms. For prophylaxis (prevention), it should be started within two days of exposure.

Administration Conditions and Adjustments

  • With or Without Food: Flumivir may be taken with or without food. Taking it with food may help improve tolerance.
  • Pediatric Dosing: Dosing for children under 13 is weight-based. For example, infants under one year old typically receive a 3 mg/kg dose twice daily.
  • Renal Impairment: The dosage must be reduced in adults with compromised kidney function (creatinine clearance le 30 mL/min).

Preparation and Missed Doses If the commercial oral suspension is unavailable, the contents of the capsules can be mixed with sweetened food or liquid for patients unable to swallow them whole. If a dose is missed, take it as soon as remembered, unless the next scheduled dose is less than 2 hours away, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flumivir

Evidence for Use in Treating Acute, Uncomplicated Flu

Research exploring Flumivir's role in treating the flu focuses primarily on short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies typically involved otherwise healthy adults, adolescents, and children. The study design required that the drug was initiated within 48 hours of a patient’s first flu symptoms. The main measures examined in this research were the time until the resolution of all major flu symptoms and the overall duration of the illness.

In this research context, studies reported how symptoms evolved in the observed populations. Findings describe patterns observed in the studies that tracked the time until patients reached symptom relief; the duration was shorter than the measurements observed in the placebo groups. This research highlights changes measured during the study period, primarily related to the resolution of symptoms capturing phases of heightened symptom activity.

Certainty remains low for some aspects of treatment. For example, efficacy is not established when administration begins more than 48 hours after symptoms first appear. Furthermore, the evidence base is heterogeneous and limited regarding the association between the drug’s use and severe outcomes, such as hospitalization rates or certain complications, in the general outpatient population.

Evidence for Use in Preventing Symptomatic Illness (Prophylaxis)

Research also explored Flumivir's use in prevention, known as prophylaxis, in studies conducted during periods of increased symptom activity. These studies involved individuals who had close, recent contact with someone who was sick with the flu, such as within a household or institutional setting.

The studies monitored the measured rates of symptomatic flu incidence, which were reported to be less frequent in the group receiving the drug compared to the group receiving placebo. Studies monitored the incidence and indicated that fewer people developed clinical symptoms following exposure.

Key areas of uncertainty include the efficacy when the drug is started more than 48 hours after symptoms appear and the effect on certain severe outcomes like hospitalization in general populations. Comparative evidence is lacking between Flumivir and other existing treatment options. Research provides insight into short-term changes, but the evidence quality varies across studies, and many of the reported outcomes were short-term and based on modest sample sizes.

Frequently Asked Questions (FAQ)

Common questions about Flumivir (FAQ)

Q: How quickly does Flumivir start working after you take it?

A: Flumivir is a prodrug, which means your body must first convert it into its active form. According to pharmacokinetics data, the active form of the drug typically reaches its highest levels in the blood approximately 3 to 4 hours after you take a dose. This conversion allows the therapeutic process to begin, aligning with the dosing frequency required to maintain effective drug levels.

Q: Can taking Flumivir make you feel tired or drowsy?

A: Official reports on the safety profile list dizziness as a common side effect of Flumivir, which is a nervous system disorder. While feelings of fatigue or tiredness are often associated with the flu illness itself, drowsiness is not consistently listed as a common adverse reaction in the official product information.

Q: Why do some people say Flumivir didn't seem to work for them?

A: Clinical studies show the greatest benefit from Flumivir when treatment is started within 48 hours of the first onset of flu symptoms. Official labeling states that the effectiveness of the drug is not established when treatment is initiated later than this 48-hour window. Initiating treatment outside of the recommended time frame is one documented reason why patients may not experience the full benefit observed in clinical trials.

Q: Is it normal to have a mild stomach ache when first starting Flumivir?

A: Yes, gastrointestinal issues are very common side effects associated with the medication, including nausea, vomiting, and abdominal pain. Official administration guidelines note that taking the medication with food may help improve the body's tolerance to these effects.

Q: Does Flumivir have any known interactions with herbal supplements?

A: Regulatory documents indicate that Flumivir is primarily eliminated through the kidneys and does not rely on the CYP450 enzyme system, which is responsible for breaking down many common medicines. This generally suggests a low potential for many drug interactions. The labeling advises that all medicines, including herbal supplements, be disclosed to a healthcare provider before starting treatment.

Q: Are there any specific foods or drinks to avoid while taking Flumivir?

A: There are no official regulatory warnings listing specific foods or drinks that must be avoided while taking Flumivir. The medication can be taken with or without food. Taking it with food is noted in the official guidance as a way to potentially help reduce the possibility of stomach upset.

Q: Are there studies showing how well Flumivir prevents complications from an illness?

A: The primary focus of clinical trials has been on reducing the duration and severity of flu symptoms. Official labeling states that the efficacy of the drug regarding severe outcomes, such as hospitalization rates or specific complications like pneumonia, has not been established in placebo-controlled studies within the general outpatient population.

Q: Is it okay to drive or operate machinery while taking Flumivir?

A: The official labeling notes that because side effects like dizziness and vertigo have been reported, patients should be cautious when driving or operating machinery. These effects could potentially impact your ability to safely perform tasks that require alertness and coordination.

Q: Why is a prescription required for Flumivir?

A: Flumivir is classified as a prescription-only medicine (POM) because it is a targeted antiviral drug. Its appropriate use, correct dosing based on indication and patient health, and monitoring of the infection requires the professional judgment and supervision of a licensed healthcare practitioner.

Q: Is there a chance the virus could become resistant to Flumivir over time?

A: Yes, regulatory surveillance reports have documented cases of reduced susceptibility to Flumivir, often referred to as resistance. This resistance can develop either during a course of treatment or through the circulation of already resistant viral strains in the community.

Q: What should be done with leftover Flumivir after the course is finished?

A: Unused medication, once the course is complete, is intended to be disposed of following local requirements and established practices, such as those for expired or unwanted medicines. Official guidelines advise against flushing the medicine down the toilet unless specifically instructed to do so by a regulated disposal program.

Q: Is Flumivir safe to take if you have asthma or other respiratory issues?

A: While treatment is often considered for individuals with underlying chronic respiratory conditions, as they are a high-risk group, the official label does not provide universal recommendations for use in these specific conditions. Eligibility is determined by a healthcare provider.

Q: Can Flumivir interact with common prescription medications like cholesterol or diabetes drugs?

A: Since the active form of Flumivir is not metabolized by the CYP450 system, which processes many common prescription drugs (including some for cholesterol and diabetes), a clinically significant interaction is generally not expected. Regulatory information indicates that patients should disclose all medicines to their prescriber.

Q: Does Flumivir only work for one type of virus, or multiple strains?

A: Flumivir is a neuraminidase inhibitor specifically approved for the treatment and prevention of illness caused by Influenza A and B viruses. It is a targeted antiviral and does not work against other pathogens, such as the viruses that cause the common cold.

Q: What is the half-life of Flumivir in the body?

A: The half-life refers to the time it takes for half of the drug to be eliminated from the body. The active metabolite of Flumivir (oseltamivir carboxylate) has an estimated half-life of approximately 6 to 10 hours. This figure informs how frequently the drug is dosed.

Q: Why do some forums mention confusion or vivid dreams as a potential side effect of Flumivir?

A: Official post-marketing reports have documented rare neuropsychiatric events—such as confusion, delirium, and hallucinations—primarily in children and adolescents. While these events may sometimes be linked to the underlying influenza illness, they have occurred shortly after starting treatment and are noted in the drug's safety information.

Q: Is it true that Flumivir works best if taken within 48 hours of symptoms starting?

A: Yes, clinical evidence and regulatory guidance support that Flumivir is most effective when treatment is initiated within two days (48 hours) of the first sign of flu symptoms. Beyond this 48-hour period, the drug’s ability to reduce the length of the illness is not established, according to clinical evidence.

Q: Why is Flumivir not used to treat the common cold?

A: Flumivir is a neuraminidase inhibitor, a specific class of drug designed to block an enzyme essential only to the influenza (flu) virus. The viruses that cause the common cold (like rhinovirus or coronavirus) do not possess this target enzyme, making Flumivir ineffective against the common cold.

Q: Can Flumivir be taken alongside the annual flu shot?

A: Yes, Flumivir can generally be taken alongside the inactivated (injection) influenza vaccine. However, it is documented to reduce the effectiveness of the live attenuated influenza vaccine (LAIV), which is the nasal spray form. Guidance on the timing of live vaccines, such as LAIV, should be sought from a healthcare provider.

Q: How important is it to take Flumivir at the exact same time each day?

A: It is important to follow the prescribed timing (e.g., twice daily or once daily) as closely as possible. Taking the doses at consistent intervals helps maintain a steady level of the active medication in your bloodstream. This consistent dosing interval is designed to help maintain drug levels within the range required to achieve the therapeutic effect.

How should Flumivir be stored and disposed of?

How to Store and Dispose of Flumivir

Flumivir (oseltamivir) must be stored in its original container at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). The capsules and dry powder must be protected from moisture, and the product must be kept out of reach of children.


Stability and Handling

Formulation Storage Condition Shelf-Life Limit
Dry Powder/Capsules 20 C to 25 C Until Expiration Date
Reconstituted Suspension Refrigerated (2 C to 8 C) 17 days
Reconstituted Suspension Room Temperature (25 C) 10 days

Do not freeze the liquid oral suspension. Unused or expired Flumivir must be disposed of according to local requirements and established local practices. Avoid flushing the medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flumivir found in:

A-Z Index: